“Vaccines Europe, the specialised vaccines group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), was created in 1991 and celebrates its 30th anniversary this year.
Vaccines Europe represents vaccine companies of all sizes operating in Europe, and currently our membership includes all the major global innovative and research-based vaccine companies, including small and medium-sized enterprises.
Vaccines are one of the most cost-effective public health tools, saving lives of individuals from birth to grave, saving costs to the society from health care systems to the whole economy and supporting freedom of being and movement. In addition and often forgotten or not known, vaccines contribute to the fight against AMR and vaccine-preventable cancers. Overall, vaccines are an instrumental public health tool to build resilient health care systems and economies.
With 30 years of continuous innovation against burdensome when not lethal vaccine-preventable diseases, Vaccines Europe represents today 14 vaccine companies, supports the value of about 20 vaccines available for routine use in Europe, has demonstrated to be a reliable innovation-driven industrial partner throughout 2 pandemics in the last 10 years (H1N1 – 2009-2010 and COVID-19 – 2020-2021), as well as the vaccine-hesitancy induced measles outbreak of 2017-2019, and is prepared to continue protecting the population with safe and efficacious innovative vaccines against more vaccine-preventable diseases over the next decades.
Throughout the next months, listen to our members to know more about what has been achieved over the last 30 years in the fight against vaccine-preventable diseases, and what can be expected for the next 30 years.”
Sibilia Quilici, Executive Director Vaccines Europe